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Null Mutations in the Filaggrin Gene (FLG)
Determine Major Susceptibility to Early-Onset
Atopic Dermatitis that Persists into Adulthood
Jonathan N.W.N. Barker1, Colin N.A. Palmer2, Yiwei Zhao3, Haihui Liao3, Peter R. Hull3, Simon P. Lee2,
Michael H. Allen1, Simon J. Meggitt4, Nicholas J. Reynolds4, Richard C. Trembath5 and W.H. Irwin McLean3
Atopic dermatitis (AD) is a common disease with a complex etiology in childhood and adult life. A significant
proportion of childhood AD is transient, but in many cases it persists into adulthood. We have recently shown
that null mutations in the filaggrin gene (FLG) are an important predisposing factor for childhood eczema and
eczema-associated asthma, but persistence to adulthood has not been analyzed. Here we studied a cohort of
adult patients with persistent AD, which had been present since early childhood. In this cohort, the combined
allele frequency of the two common FLG null variants was 0.270 (cf. population frequency 0.046). This represents
an odds ratio of 7.7 with 95% confidence interval of 5.3–10.9 and a w2 P-value of 1.7 1053. Our data conclusively
demonstrate that identification of FLG null alleles is an indicator of a poor prognosis in AD, predisposing to a
form of eczema that starts in early infancy and persists into adulthood. This study helps to further define the
nature of the AD phenotype associated with FLG null alleles.
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INTRODUCTION
The filaggrin gene, FLG, is situated in the epidermal
differentiation complex 1q21 (Mischke et al., 1996), a dense
cluster of genes encoding proteins involved in terminal
differentiation of the epidermis and a shared susceptibility
locus for AD (ATOD2; OMIM #605803) and psoriasis
(PSORS4; OMIM #603935). The stratum corneum consists
of tightly compacted, highly chemically crosslinked layers of
dead cells that form a physical barrier to reduce water loss
and protect the body from its chemical, antigenic, and
allergenic environment (Candi et al., 2005). Profilaggrin is the
main protein component of the keratohyalin granules within
the last living cell layers of the epidermis (Irvine and McLean,
2006). Upon terminal differentiation of these granular cells to
form the squames, the 4400 kDa polyprotein profilaggrin is
proteolytically processed into 10–12 copies of the 37 kDa
filaggrin peptide, the functional end-product of the FLG gene
(Steinert et al., 1981; Dale et al., 1985; Gan et al., 1990).
These peptides rapidly aggregate the keratin cytoskeleton and
bring about squame formation. Thus, filaggrin is essential for
the cell compaction process that precedes chemical cross-
linking and skin barrier formation.
FLG has an unusual structure where the vast majority of
profilaggrin is encoded by the third and final exon, which
consists of 10–12 tandemly repeated copies of the B1 kb
filaggrin sequence (Smith et al., 2006). Recently, we found that
about 10% of people of European origin carry one of two loss-
of-function mutations in FLG, designated R501X and 2282del4
(Smith et al., 2006). Both of these mutations lead to premature
termination codons within repeat 1 and were shown biochemi-
cally to cause complete absence of processed filaggrin in the
epidermis (Smith et al., 2006). Less common mutations, located
centrally in the filaggrin repeat domain, have also been
identified (Sandilands et al., 2006). These mutations were
proven to cause ichthyosis vulgaris (dry, scaly skin) with a mild
phenotype in heterozygotes or a much more marked phenotype
in homozygotes or compound heterozygotes (Sandilands et al.,
2006; Smith et al., 2006). Importantly, it was subsequently
shown that these mutations are a major predisposing factor for
atopic dermatitis (AD; Palmer et al., 2006).
In 45% of children with AD, onset occurs within the first
6 months of life; in 60%, AD occurs during the first 12 months;
and at least 85% are affected before their fifth birthday (Kay
et al., 1994). In children with onset at age less than 2 years,
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20% will have persistent AD and a further 17% will have
intermittent symptoms by age 7 years (Illi et al., 2004). In
contrast, onset after adolescence is only recorded in 16.8% of
adults with AD (Williams and Strachan, 1998; Ozkaya,
2005). Here, we present data strongly confirming that filag-
grin mutations are a major genetic factor in AD. Significantly,
we show that carrying one or two filaggrin null alleles can
lead to early-onset AD that persists well into adulthood.
RESULTS AND DISCUSSION
In our cohort of 163 adults with childhood onset persistent
AD, we observed a greatly elevated frequency of the two FLG
null alleles that are common in European populations, R501X
and 2282del4. Specifically and strikingly, the combined
allele frequency for these two FLG null variants was 0.270 in
the AD cohort in contrast to 0.046 in the ethnically matched
population controls, that is, there was almost 6-fold over-
representation of the null alleles in the AD cohort. Another
way of looking at this data is that 8.8% of the general
population carry one or more FLG null alleles, whereas 42%
of the AD cohort carry one or more of these FLG alleles. The
FLG genotype data in the AD cohort and in a group of 1,463
ethnically matched population controls of anonymous
phenotype are summarized in Table 1. The association
between the FLG null variants and AD was highly statistically
significant for each of the two common null variants.
Specifically, for R501X, the w2 P-value was 1.0 1027,
and for 2282del4, the P-value was 3 1026. The fact that
each of the individual FLG variants produced highly
significant P-values gives within-study replication. Combin-
ing both null alleles gave an extremely significant w2 P-value
of 1.71053 compared to the control population. The
combined genotype data also gave an odds ratio of 7.7 with
95% confidence interval of 5.3–10.9 using Fisher’s exact test,
showing that the association is highly robust using more than
one of the recognized statistical methods for analysis of this
type of case:control association study.
Atopic disease (atopy) affects up to 20% of children in the
developed world (Holgate, 1999). Atopy is characterized by
AD, which is often present from early childhood and often
accompanied later in life by a range of allergic diseases,
importantly including asthma, food allergy and allergic
rhinitis (hay fever). Recent genetic evidence in the form of
highly prevalent FLG null alleles in atopic individuals
suggests that the primary defect is a failure of skin barrier
function, allowing abnormally enhanced cutaneous presen-
tation of antigens, allergens and chemicals to the immune
system (Hudson, 2006; Palmer et al., 2006; Weidinger et al.,
2006). About 9% of individuals in a number of European
populations studied to date carry one of the two common
FLG null alleles, that is, the population allele frequency is
about 0.045. These null alleles have now been shown to
strongly associate with AD in several distinct cohorts. In a
small Irish cohort of children attending a pediatric dermatol-
ogy department with severe AD, the FLG null-allele
frequency was 0.336; in a large German cohort of almost
500 families, ascertained through probands attending hospi-
tal with AD and including their siblings, the null-allele
frequency in individuals with AD was 0.249 (Weidinger
et al., 2006); and in a cohort of Scottish children, ascertained
through asthma, who had both asthma and AD, the allele
frequency was 0.254. A lower carrier rate of 0.190 of AD-
diagnosed individuals was seen in children born to mothers
with asthma in a community-based prospective cohort from
Denmark (Palmer et al., 2006). In this current cohort of adult
patients with persistent AD attending hospital dermatology
departments, the FLG null-allele frequency was strikingly
high at 0.270. These data showing high representation of FLG
null alleles in this well-phenotyped adult AD cohort help to
better define AD. In particular, FLG-null or FLG-haploinsuffi-
cient AD appears to be a key factor in 20–25% of pediatric
AD cases in several communities and may be associated
with increased severity in childhood (Palmer et al., 2006;
Weidinger et al., 2006). Our data here suggest that FLG-
associated AD represents a significant proportion of persistent
disease through to adulthood as 42% of the childhood-onset,
adult-persistent AD cohort examined here carried one or
more FLG null alleles. A large population-based study will be
necessary to further validate these early interpretations and to
gain detailed information about the penetrance and age
milestones for the various atopic phenotypes associated with
FLG variants.
Table 1. FLG null variant genotypes in adults with atopic dermatitis
R501X 2282del4 Combined null genotype
Genotypes Control population AD cohort Control population AD cohort Control population AD cohort
AA 1,381 121 1,414 129 1,334 94
Aa 79 33 49 30 124 49
aa 3 9 0 4 5 20
Totals 1,463 163 1,463 163 1,463 163
P=1.0 1027 P=31026 P=1.7 1053
AD, atopic dermatitis; AA, homozygous wild type for FLG null variant; Aa, heterozygous for either of the common FLG null alleles R501X or 2282del4;
aa, homozygous or compound heterozygous for FLG null alleles R501X or 2282del4.
For the combined genotype data, note that compound heterozygotes (n=7) are counted as ‘‘aa’’. For example, in the AD cohort, the total is 20 (nine R501X
homozygotes, four 2282del4 homozygotes, and seven R501X/2282del4 compound heterozygotes).
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In biological terms, filaggrin is essential for bringing about
a cascade of biochemical and cellular events leading to the
formation of the stratum corneum – the dead, chemically
crosslinked cell layers within which the skin barrier function
resides (Listwan and Rothnagel, 2004). We have shown
previously that the stratum corneum is poorly formed in
filaggrin-null individuals (Smith et al., 2006) and we
hypothesize that this leads to increased passage of antigens,
allergens, and chemicals through the epidermis where one or
more of these agents invoke an immune response, manifest-
ing as the various features of atopy (Irvine and McLean,
2006). Since skin barrier formation is impaired from birth in
individuals carrying one or more FLG null alleles, it is logical
to expect that the onset of AD is both early and persistent into
adulthood. Similarly, longitudinal studies of patient behavior
and/or micro-environment (Williams et al., 2004) may help
identify trigger factors that act upon the FLG-null or FLG-
haploinsufficient genotypes to produce AD and other allergic
phenotypes. Such data will inform future genetic testing
regimens and perhaps shed light on beneficial behavioral or
environmental interventions.
One can postulate that changes in the epidermal barrier
lead to inflammation in the skin, which once established is
difficult to reverse (Hudson, 2006). To this end, it is of note
that prevalence of AD in adulthood is greater in individuals
who undertake occupations that provoke irritation of the skin,
for example, hairdressers or caterers (Holm and Veierod,
1994). Therapeutic strategies aimed at correcting this barrier
early are therefore likely to have long-term beneficial effects.
MATERIALS AND METHODS
Study populations
All DNA samples were collected with institutional research ethics
committee approval (King’s College London and University of
Newcastle) and informed consent that complies with all the
Declaration of Helsinki Principles. One hundred and sixty-three
adults with persistent AD were recruited from hospital-based
dermatology clinics in England. All subjects were of white British
ancestry. All study subjects met the UK Working Party definition of
AD as interpreted by an experienced dermatologist (J.N.B., S.M., or
N.J.R.) (Williams et al., 1994a, b). The majority of individuals
recruited had an age of onset of less than 16 years of age (92%). In
five cases (3% of the cohort), the precise age of onset was o18 but
was not precisely known. In seven cases (4%), the age of onset was
421 years. The AD cohort was reported previously (Veal et al.,
2005) and the demographics and clinical parameters of this study
cohort are summarized in Table 2. A total of 1463 population
controls were used, who were also of white British ancestry. DNA
was prepared from whole blood using standard procedures.
Filaggrin genotyping
Genotyping for R501X was performed using a TAQMAN-based
allelic discrimination assay (Applied Biosystems, Foster City, CA).
Standard procedures were used based on Applied Biosystems
reagents and 10 ml reaction volumes. Allelic discrimination was
assessed using an Applied Biosystems 7700 sequence detection
system. Probes and primers were as described previously (Palmer
et al., 2006). Mutation 2282del4 was genotyped by sizing of a
fluorescently labelled PCR fragment on an Applied Biosystems 3100
or 3730 DNA sequencer as described previously (Palmer et al.,
2006).
Statistical analysis
All statistical analysis in the association study was performed using
SPSS for Windows, v.11.5 or Instat 3 for Macintosh (Graphpad
Software Inc., San Diego, CA). Allele frequencies were compared
using Pearson’s w2 tests of the three genotype frequencies (AA, Aa,
aa); odds ratios for dominant models (AA vs aX) were determined
using Fisher’s exact tests and binary logistic regression. All P-values
shown are not corrected for multiple testing as all the tests of the
primary hypotheses firmly rejected the null hypothesis. All variants
were in Hardy–Weinberg equilibrium. Note that when combining
Table 2. Demographic data of AD cohort
Number of patients 163
Ethnicity White British (51 NE England; 112 SE England)
Mean age at examination (years) 36.4 (range 16–82)
Mean age of AD onset 3.9 years (3 months–44 years)
Age of onset breakdown (years)
Birth–2 115 (73%)
3–5 21 (13%)
6–10 9 (5%)
11–15 2 (1%)
16–20 4 (2%)
421 7 (4%)
o18 but not exact age of onset unknown 5 (3%)
IgE Mean=5,752 kU/l, range 23–71,000 kU/l
94% cases had elevated IgE (470 kU/l)
AD, atopic dermatitis; NE, northeast; SE, southeast.
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the two null genotypes, ‘‘AA’’ refers to an individual who carries
neither FLG mutation; ‘‘Aa’’ refers to an individual who is hetero-
zygous for either R501X or 2282del4; and ‘‘aa’’ refers to individuals
homozygous for R501X, or homozygous for 2282del4, or compound
heterozygous for R501X/2282del4 (Table 1).
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